BOSTON & TOKYO & KYOTO, Japan--(BUSINESS WIRE)--
PAREXEL International Corporation (PRXL), a leading global biopharmaceutical services provider, and Kyoto Pharmaceutical University (KPU), a private pharmacy and science university, today announced the new Joint Program for Clinical Research and Clinical Trial Management. The academic program offers undergraduate students an accredited, seven-week course designed to prepare them for careers in the biopharmaceutical industry.
The collaboration is intended to meet the needs of a growing number of Japanese biopharmaceutical companies conducting clinical research inside and outside of Japan as part of global drug development initiatives. The course combines PAREXEL®'s extensive regulatory and clinical research expertise with Kyoto Pharmaceutical University's extensive experience developing highly-specialized research abilities in their "pharmacist-scientists" students. All classes will be conducted in English by non-Japanese lecturers from the PAREXEL Academy and are consistent with global clinical trial standards and practices. The first session begins in KPU's fiscal year 2016 and will be offered annually.
"In Japan, clinical trial management is not widely taught in an academic setting. In partnership with Kyoto Pharmaceutical University, we are offering a unique educational program that provides a functional foundation in clinical research and clinical trial management. We believe this program is an innovative way to accelerate the penetration of global standards of clinical research in Japan while also helping to address the current clinical research workforce shortage in the country," said Shogo Nakamori, Corporate Vice President, Asia-Pacific and General Manager, PAREXEL Japan.
Ken-ichi Inui, President, Kyoto Pharmaceutical University, commented that "Kyoto Pharmaceutical University provides an integrated education over a six-year period, with the purpose of training pharmacists with advanced specialized skills and research capabilities, that is, 'pharmacist-scientists'. In addition, with an interest towards globalization in 2012, we decided to use English instead of Japanese for graduation-thesis presentations by six-year students. Through our partnership with the PAREXEL Academy, KPU's Joint Program for Clinical Research and Clinical Trial Management will benefit students interested in working in the pharmaceutical industry, hospitals and regulatory affairs."
PAREXEL established operations in Japan in 1995 and has more than 1,000 employees based in Tokyo, Kobe and Osaka. The Company provides clinical research services, consulting and technology offerings to drug developers. In addition, for more than a decade, the PAREXEL Academy has designed and implemented a wide range of learning programs tailored to enable clinical research management practices for learners inside and outside of PAREXEL in Asia, Europe, and the United States. Since inception, approximately 1,000 students have graduated from the Academy's programs.
About Kyoto Pharmaceutical University
Kyoto Pharmaceutical University (KPU) was founded as a pre-pharmacy course in Kyoto Private German School in 1884 and is the second oldest private school of pharmacy in Japan. Over 22,000 graduates of KPU have contributed greatly, with high appraisal, in pharmaceutical companies, hospitals, pharmacies, academia, and administrative agencies. The new six-year system in undergraduate pharmacy education of Japan started in 2006. KPU puts special emphasis on postgraduate education as well as undergraduate education. A four-year doctorate course which follows upon the six-year undergraduate course is important for the training of future leaders (pharmacists with PhD) in various areas related with pharmaceutical sciences. In 2012, KPU established a four-year doctorate course, consisting of "basic pharmacy course," "clinical pharmacy course," "cancer research course," specializing in cancer study in cooperation with some medical schools, and "regulatory science course" linked with the Pharmaceutical and Medical Devices Agency, Japan.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,620 employees in the first quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings, including expense savings from the $30 – $45 million restructuring charge disclosed in the press release dated June 23, 2015; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisition Quantum Solutions India, or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.